Cathie's Ark LogoCathie's Ark
Trading Floor Community IconFrom the Trading Floor:
CRISPR Therapeutics AG Logo

ARKK Holdings of CRISPR Therapeutics (CRSP) - Updated Daily

Lock Icon
Date
Direction
Shares
Fund Weight
Fund
September 14, 2021BUY145000.01%ARKK
September 10, 2021BUY170000.01%ARKK
September 9, 2021BUY369900.02%ARKK
August 19, 2021BUY300000.0168%ARKK
August 18, 2021BUY184360.0104%ARKK

Key Statistics

🕵🏼Found In🏷Last Price
ARKKARKG$116.30
⚖️Weighting🧢Market Cap
2.71%$8.86b
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
169.83
🏋️‍♀️Weight Rank Across All Funds🌏Country
17🇨🇭Switzerland
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$58.636.41%
Description
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
Website
crisprtx.com